SPPI(Delisted)
Spectrum PharmaceuticalsยทNASDAQ
--
--(--)
SPPI Profile
Spectrum Pharmaceuticals, Inc.
A biopharmaceutical company focused on novel and targeted oncology
11500 South Eastern Avenue, Suite 240, Henderson, Nevada 89052
--
Spectrum Pharmaceuticals, Inc., is a biotechnology company with a full range of commercial and drug development operations focused on oncology. The Company was incorporated as a Delaware corporation in Colorado in December 1987, initially as Amelix Financing Corporation, in August 1996 as NeoTherapeutic Corporation, in June 1997 as a Delaware Corporation, and in December 2002 as Spectrum Pharma Corporation. This company is a diversified pipeline whose strategy includes acquisition, development and commercialization of late-stage clinical and commercialization. The company currently sells three oncology drugs: FUSILEV, FOLOTYN, ZEVALIN and two drugs: apaziquone and belinostat, as well as a diversified pipeline of new drug candidates in late-stage development. The company integrates its internal scientific research team, including its formulation development, clinical development, medical research, legal affairs, biostatistics and data management, and builds the marketing business infrastructure for its desired products. The company unites collaborating experts from around the world to help real-time their strategy. In 2012, Apaziquone initiated research with strategic partner Allergan in the third phase of a large clinical trial for non-muscle invasive bladder cancer, while maintaining cooperation with Nippon Kayaku and Handok Pharmaceuticals. Spectrum Pharma and TopoTarget are strategically partnering in the second phase of a clinical trial to study multiple adaptive symptoms, namely relapsed or refractory T-lymphocyte carcinoma.
